BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
Ahuja, Sunil K.	Professor of Medicine, Microbiology, Immunology and Biochemistry

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (IF APPLICABLE)	YEAR(S)	FIELD(S) OF STUDY
Armed Forces Medical College Pune, Maharashtra, India	MD	1979-1983	Medicine
University of Alberta, Edmonton Alberta, Canada	M.Sc.	1985 - 1986	Immunology/Medicine

RESEARCH AND PROFESSIONAL EXPERIENCE:

Professional Experience

1983 - 1984 Intern, Safdarjang Hospital, University of Delhi, New Delhi, India.
1986 - 1990 Intern, Resident, & Chief Resident, SUNY Health Science Center at Brooklyn, Brooklyn, NY.
1990 - 1993 Infectious Diseases Fellow, NIAID, National Institutes of Health, Bethesda, MD.
1993 - 1996 Medical and Senior Staff Fellow, Laboratory of Host Defenses, NIAID, NIH, Bethesda, MD.
1996 - Current Staff Physician, South Texas Veterans Health Care System, San Antonio, TX.
1996 - 2002 Assistant and Associate (1999-2002) Professor of Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX.
2001 - 2002 Associate Chair of Medicine for Research, UTHSCSA, San Antonio, TX.
2001 - Current Director, VA Center for AIDS and HIV Infection, STVHCS, San Antonio, TX.
2002 - Current Professor of Medicine, Microbiology/Immunology & Biochemistry, UTHSCSA, San Antonio, TX.

Honors and Awards: Doris Duke Distinguished Clinical Scientist (2009); Association of American Physicians (Elected 2006), 2006 President's (UTHSCSA) Distinguished Scholar; NIH MERIT award (2005), President's Council Chair for Excellence in Medical Research (endowed chair); AARR6 (AIDS/NIH) chartered member (2006-), AARR1 (AIDS) Study Section chartered member (2000-2005); ad-hoc for several NIH study sections; VA Career Development and Research Center Review panels (2004-); American Society for Clinical Investigation (elected 2002); 2001 Elizabeth Glaser Scientist (Pediatric AIDS Foundation); Burroughs Wellcome Clinical Scientist in Translational Research (2001); Council of Tobacco Research, USA, Research Scholar (1997-2000).

Selected Peer- Reviewed Publications from 73

1. **Ahuja SK**, Ozcelik T, Milatovitch A, Francke U, Murphy PM. Molecular evolution of the human interleukin-8 receptor gene cluster. ***Nat Genet.*** 1992 Sep;2(1):31-6.
2. **Ahuja SK**, Murphy PM. Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. ***J Biol Chem.*** 1993 Oct 5;268(28):20691-4.
3. **Ahuja SK**, Shetty A, Tiffany HL, Murphy PM. Comparison of the genomic organization and promoter function for human interleukin-8 receptors A and B. ***J Biol Chem.*** 1994 Oct 21;269(42):26381-9.
4. **Ahuja SK**, Gao JL, Murphy PM. Chemokine receptors and molecular mimicry. ***Immunol Today.*** 1994 Jun;15(6):281-7.
5. Combadiere C, **Ahuja SK**, Van Damme J, Tiffany HL, Gao JL, Murphy PM. Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. ***J Biol Chem.*** 1995 Dec 15;270(50):29671-5.
6. Combadiere C, **Ahuja SK**, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. ***J Biol Chem.*** 1995 Jul 14;270(28):16491-4.
7. Combadiere C, **Ahuja SK**, Murphy PM. Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. ***DNA Cell Biol***. 1995 Aug;14(8):673-80.
8. Combadiere C, **Ahuja SK**, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. ***J Leukoc Biol.*** 1996 Jul;60(1):147-52.
9. Combadiere C, **Ahuja SK**, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. ***J Biol Chem.*** 1996 May 3;271(18):11034.
10. **Ahuja SK**, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. ***J Biol Chem.*** 1996 Aug 23;271(34):20545-50.
11. **Ahuja SK**, Lee JC, Murphy PM. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. ***J Biol Chem.*** 1996 Jan 5;271(1):225-32.

12. Alkhatib G, Ahuja SS, Light D, Mummidi S, Berger EA, **Ahuja SK**. CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion. ***J Biol Chem*.** 1997 Aug 8;272(32):19771-6.
13. Mummidi S, Ahuja SS, McDaniel BL, **Ahuja SK**. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. ***J Biol Chem*.** 1997 Dec 5;272(49):30662-71.
14. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, **Ahuja SK**. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. ***Nat Med***. 1998 Jul;4(7):786-93.
15. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, Cabrera S, McBride M, Cao XH, Merrill G, O'Connell P, Bowden DW, Freedman BI, Anderson SA, Walter EA, Evans JS, Stephan KT, Clark RA, Tyagi S, Ahuja SS, Dolan MJ, **Ahuja SK**. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. ***Proc Natl Acad Sci U S A*.** 1999 Oct 12;96(21):12004-9.
16. Sato N, Kuziel WA, Melby PC, Reddick RL, Kostecki V, Zhao W, Maeda N, **Ahuja SK**, Ahuja SS. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. ***J Immunol*.** 1999 Nov 15;163(10):5519-25.
17. Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan MJ, Melby PC, **Ahuja SK**. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. ***J Immunol***. 1999 Oct 1;163(7):3890-7.
18. Mummidi S, Bamshad M, Ahuja SS, Gonzalez E, Feuillet PM, Begum K, Galvis MC, Kostecki V, Valente AJ, Murthy KK, Haro L, Dolan MJ, Allan JS, **Ahuja SK**. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. ***J Biol Chem*.** 2000 Jun 23;275(25):18946-61.
19. Quinones M, **Ahuja SK**, Melby PC, Pate L, Reddick RL, Ahuja SS. Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. ***J Exp Med*.** 2000 Aug 21;192(4):507-16.
20. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A, Duggirala R, Williams K, Mummidi S, Clark RA, Ahuja SS, Dolan MJ, Bologna R, Sen L, **Ahuja SK**. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. ***J Infect Dis*.** 2001 Jun 1;183(11):1574-85.
21. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, Anderson SA, Walter EA, Stephan KT, Hammer MF, Mangano A, Sen L, Clark RA, Ahuja SS, Dolan MJ, **Ahuja SK**. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. ***Proc Natl Acad Sci U S A***. 2001 Apr 24;98(9):5199-204.
22. Mummidi S, Catano G, Lam L, Hoefle A, Telles V, Begum K, Jimenez F, Ahuja SS, **Ahuja SK**. Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms. Inter-individual variation in expression of DC-SIGN transcripts. ***J Biol Chem*.** 2001 Aug 31;276(35):33196-212.
23. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, **Ahuja SK**. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. ***Proc Natl Acad Sci U S A***. 2002 Oct 15;99(21):13795-800.
24. Bamshad MJ, Mummidi S, Gonzalez E, Ahuja SS, Dunn DM, Watkins WS, Wooding S, Stone AC, Jorde LB, Weiss RB, **Ahuja SK**. A strong signature of balancing selection in the 5' cis-regulatory region of CCR5. ***Proc Natl Acad Sci U S A*.** 2002 Aug 6;99(16):10539-44.
25. **Ahuja SK**, Catano G. Sharing is caring, except when it comes to HLA-class-I alleles in HIV-1 transmission. ***Lancet*.** 2004 Jun 26;363(9427):2103-4.
26. Quinones MP, **Ahuja SK**, Jimenez F, Schaefer J, Garavito E, Rao A, Chenaux G, Reddick RL, Kuziel WA, Ahuja SS. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. ***J Clin Invest*.** 2004 Mar;113(6):856-66.
27. Wooding S, Stone AC, Dunn DM, Mummidi S, Jorde LB, Weiss RK, **Ahuja S**, Bamshad MJ. Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5. ***Am J Hum Genet***. 2005 Feb;76(2):291-301.
28. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell R J, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, **Ahuja SK**. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. ***Science*,** 2005 Mar 4;307(5714):1434-40.
29. Burns JC, Shimizu C, Gonzalez E, Kulkarni H, Patel S, Shike H, Sundel RS, Newburger JW, **Ahuja SK**. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. ***J Infect Dis*,** 2005 Jul 15;192(2):344-9.
30. Sundrud MS, Vancompernolle SE, Eger KA, Bruno TC, Subramaniam A, Mummidi S, **Ahuja SK**, Unutmaz D.

Transcription factor GATA-1 potently represses the expression of the HIV-1 coreceptor CCR5 in human T cells and dendritic cells. ***Blood,*** 2005 Nov 15;106(10):3440-8.

31. **Ahuja SK**, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks et al. A plea for justice for jailed medical workers. ***Science,*** 2006 Nov 10;314(5801):924-5.
32. Silverberg MJ, Wegner SA, Milazzo MJ, McKaig RG, Williams CF, Agan BK, Armstrong AW, Gange SJ, Hawkes C, O'Connell RJ, **Ahuja SK**, Dolan MJ. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. ***AIDS,*** 2006 Jul 13;20(11):1531-8.
33. Mummidi S, Adams LM, VanCompernolle SE, Kalkonde M, Camargo JF, Kulkarni H, Bellinger AS, Bonello G, Tagoh H, Ahuja SS, Unutmaz D, **Ahuja SK**. Production of specific mRNA transcripts, usage of an alternate promoter, and octamer-binding transcription factors influence the surface expression levels of the HIV coreceptor CCR5 on primary T cells. ***J Immunol.*** 2007 May 1;178(9):5668-81.
34. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, **Ahuja SK**, Klasse PJ, Moore JP. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. ***Virology.*** 2007 Aug 1;364(2):281-90.
35. Mamtani M, Rovin B, Brey R, Camargo JF, Kulkarni H, Herrera M, Correa P, Holliday S, Anaya JM, **Ahuja SK**. CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus. ***Ann Rheum Dis.*** 2007 Nov 1.
36. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, **Ahuja SK**, Ahuja SS. CC chemokine receptor 5 influences late-stage atherosclerosis. ***Atherosclerosis.*** 2007 Nov;195(1):e92-103.
37. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, **Ahuja SK**. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. ***Nat Immunol.*** 2007 Dec;8(12):1324-36.
38. **Ahuja SK**, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. ***Nat Med.*** 2008 Apr;14(4):413-20.
39. Moore JP, Klasse PJ, Dolan MJ, **Ahuja SK**. AIDS/HIV. A STEP into darkness or light? ***Science.*** 2008 May 9;320(5877):753-5.
40. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, **Ahuja SK**. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. ***Proc Natl Acad Sci U S A.*** 2008 Jun 24;105(25):8717-23.
41. Catano G, Agan BK, Kulkarni H, Telles V, Marconi VC, Dolan MJ, **Ahuja SK**. Independent effects of genetic variations in Mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations. ***J Infect Dis***. 2008 Jul 1;198(1):72-80.
42. He W, Neil S, Kulkarni H, Wright E, Agan BK, Marconi VC, Dolan MJ, Weiss RA, **Ahuja SK**. Duffy Antigen Receptor for Chemokines (DARC) mediates *Trans*-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. ***Cell Host & Microbe***, 2008 Jul 17;4(1):52-62.
43. Kulkarni H, Agan BK, Marconi VC, O'Connell RJ, Camargo JF, He W, Delmar J, Phelps KR, Crawford G, Clark RA, Dolan MJ, Ahuja SK. CCL3L1-CCR5 genotype improves the assessment of AIDS risk in HIV-1-infected individuals. ***PLoS ONE***. 2008 Sep 8; 3(9):e3165.
44. Mummidi S, Bonello GB, **Ahuja SK**. Confirmation of differential binding of Interferon Regulatory Factor-1 (IRF-1) to the functional and HIV disease-influencing -2578 A/G polymorphism in CCL2. ***Genes Immun.*** 2008 Oct 16; Epub ahead of print.
45. Catano G, Kulkarni H, He W, Marconi VC, Agan BK, Landrum M, Anderson S, Delmar J, Telles V, Song L, Castiblanco J, Clark RA, Dolan MJ, **Ahuja SK**. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. ***PLoS ONE***, 2008; 3(11):e3636.
46. Kulkarni H, Marconi VC, Agan BK, McArthur C, Crawford G, Clark RA, Dolan MJ, **Ahuja SK**. Role of CCL3L1/CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. ***PLoS ONE***, 2008;3(11):e3671.
47. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, **Ahuja SK**. Reply to Pomara et al and Valcour et al: Age and the *APOE- ε4/ ε4* genotype in HIV-1-associated dementia. ***Proc Nat Acad Sci USA***, 2008; 105(41):E67-E68.
48. Camargo JF, Quinones MP, Mummidi S, Srinivas S, Gaitan AA, Begum K, Jimenez F, Vancompernolle S, Unutmaz D, Ahuja SS, **Ahuja SK**. CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation. ***J Immunol,*** 2009 Jan 1;182(1):171-182.
49. Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, Srinivas S, He W, Anderson S, Marconi VC, Dolan MJ, **Ahuja SK**. Responsiveness of T cells to IL-7 is associated with higher CD4+ T cell counts in HAART-treated, viral load-suppressed, HIV-1-positive individuals. ***J Infect Dis***, 2009; Jun 15; 199(12): 1872-1882.
50. Shostakovich-Koretskaya L, Catano G, Chykarenko ZA, He W, Gornalusse G, Mummidi S, Sanchez R, Dolan MJ, Ahuja SS, Clark RA, Kulkarni H, **Ahuja SK**. Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-

AIDS susceptibility in Ukrainian children. ***AIDS*** 2009; 23(6):679-688.

51. Gornalusse G, Mummidi S, He W, Silvestri G, Bamshad M, **Ahuja SK**. CCL3L Copy Number Variation and the Co-Evolution of Primate and Viral Genomes. ***PLoS Genet***, 2009,5:e1000359.
52. He W, Marconi VC, Castiblanco J, Kulkarni H, Clark R, Dolan MJ, Weiss RA, **Ahuja SK**. Association of Duffy Antigen Genotypes with HIV-AIDS Susceptibility, ***Cell Host & Microbe***, 2009; 5(5): 418-419.
53. Kulkarni H, Marconi VC, He W, Landrum ML, Okulicz JF, Delmar J, Kazandjian D, Castiblanco J, Ahuja SS, Wright EJ, Weiss RA, Clark RA, Dolan MJ, **Ahuja SK**. The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. ***Blood***. 2009; Sep 24;114(13):2783-92.
54. Mamtani M, Anaya J-M, He W, **Ahuja SK**. Association of copy number variation in the *FCGR3B* gene with risk of autoimmune diseases. ***Genes Immun***. 2009, Sep 10, [Epub ahead of print].

Research Support :

ACTIVE

1. PI: Veterans Administration; 10/1/02 – 9/30/11; "VA Research Center for AIDS and HIV Infection"; The goals of this Center grant are to understand the host immunogenetic mechanisms that influence HIV pathogenesis in a multidisciplinary method. Award Amount: US $300,000 dollars Percent Effort: 15%.
2. PI: R01 AI046326; 4/1/00 – 2/28/10; NIH/NIAID - MERIT AWARDED in 2005; "Host Genetic Determinants of HIV Pathogenesis"; This project examines the role of various host genes in HIV pathogenesis. Award Amount: US $445,131 dollars Percent Effort: 10%.
3. Co-PI: R01 HL069413; 2/1/06 – 1/31/11; NIH/NHLBI; PI: Dr. Jane Burns-UCSD; "Genetic Markers and Gene Expression in Kawasaki Disease"; This project will examine the host genetic determinants of Kawasaki disease. Award Amount: US $400,000 dollars Percent Effort: 5%.
4. Co-PI: N01 NH22005; 9/1/07-8/31/10; PI: Dr. Igor Grant-UCD; "CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER)"; this project will examine the prevalence and incidence of neurological dysfunction referable to HIV infection. Award Amount: US $10,000 dollars Percent Effort: 1%.
5. Co-PI: 1PO1AI074621-01; 3/15/08-2/28/13; PI: Dr. Susan Little-UCSD; "Determinants of HIV Transmission"; This grant will investigate the role of CCL3L1/CCR5 and other host factors in transmission. Award Amount: US $290,434 dollars Percent Effort: 5%.
6. Co-PI: 1P01AI071713-01A1; 2/9/04-08/31/10; PI: Dr. Rich Hecht-UCSF; "The Biology of HIV Transmission"; this grant will investigate the role of CCL3L1/CCR5 and other host factors in transmission. Award Amount: US $252,833 dollars Percent Effort: 5%.
7. PI: Doris Duke Distinguished Clinical Scientist Award Number 2008088; 1/1/09-12/31/13; Doris Duke Charitable Foundation, "Immunogenetic Rheostats of HIV-1 transmission, keys for vaccine development"; This grant is focused on understanding the role of Host Genetics in HIV-AIDS susceptibility using cohorts of mother-child transmission and the role of epigenetics. Award Amount: US $1,500,000 dollars Percent Effort: 30%.
8. Co-PI: U.S. Civilian Research and Development Foundation (CRDF); UKB1-2931-DN-08; 2/9/09-1/31/11; "Host Genetic Determinants of HIV-AIDS Susceptibility and HAART Response"; This grant is focused in the elucidation of variation in host factors for HIV-1 Vertical Transmission and Progression Disease in Ukrainian Children. Award Amount: US $10,000 dollars Percent Effort: 0%.
9. Voelcker Foundation; 07/01/09 – 06/30/10; Genetic & Epigenetic Mechanisms Underlying Autoimmune Arthritis". This grant is focused in the investigation of the genetic factors involved in the development of Autoimmune Arthritis. Award Amount: US $500,000 dollars Developmental grant.
10. Co-PI: NIH 5R01 MH078748-03; 06/01/09-05/31/12; PI: Dr Tom Marcotte; "NeuroAIDS in India". This grant will investigate and define the CCR5 haplotypes as well as CCL3L1 copy number, MCP-1 and RANTES. Award Amount: US $45,999 dollars Percent Effort: 1%.

PENDING

1. PI: NIH; R01 "CCR5 Regulation and Promoter Variants in HIV-1". This grant will study the gene regulation of CCR5, a protein that is critical to HIV susceptibility. Amount requested: US $2,061,806 dollars. Percent effort: 15%.
2. PI: NIH; R01 "Host Genetic Determinants of Mother-to-Child HIV-AIDS Susceptibility". This grant will explore the genetic variation of the HIV-AIDS susceptibility in cohorts of perinatally infected children from the Ukraine and Argentina". Amount requested: US $2,762,369 dollars. Percent effort: 15%.
3. PI: CPRIT; "Host genetic, host microRNA and viral determinants of cancer susceptibility during HIV infection: a model for defining host-viral cancer susceptibility factors." This grant will study the genetics and epigenetics host factors involved in malignancy in HIV-infected individuals. Amount requested: US $2,387,908 dollars Percent effort: 30%.